Literature DB >> 4007019

Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity.

W R Miller, J Telford, J M Dixon, R A Hawkins.   

Abstract

Androgen receptor activity was measured in tumours from 122 patients with breast cancer. Forty-two tumours (34%) possessed androgen receptors at levels varying from 17 to 210 fmol/mg cytosol protein (mean value 68). No relationship was detected between androgen receptors and menopausal status of the patients and whether or not lymph nodes were invaded with tumour at the time of biopsy. There were, however, significant positive correlations between the presence of androgen receptors and that of oestrogen (P less than 0.05) and of progestogen receptors (P less than 0.025). These relationships suggest that androgen receptors may be of value in predicting the hormone responsiveness of breast tumours but definitive proof of this requires clinical follow-up of the patients studied.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4007019     DOI: 10.1016/0277-5379(85)90049-5

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  18 in total

1.  Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer.

Authors:  Walter Schippinger; Peter Regitnig; Nadia Dandachi; Klaus-Dieter Wernecke; Thomas Bauernhofer; Hellmut Samonigg; Farid Moinfar
Journal:  Virchows Arch       Date:  2006-04-21       Impact factor: 4.064

2.  Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study.

Authors:  D J Perrault; D M Logan; D J Stewart; V H Bramwell; A H Paterson; E A Eisenhauer
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

3.  Androgen receptors, serum androgen levels and survival of breast cancer patients.

Authors:  M Langer; E Kubista; M Schemper; J Spona
Journal:  Arch Gynecol Obstet       Date:  1990       Impact factor: 2.344

4.  Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer.

Authors:  W R Miller; D M Watson; W Jack; U Chetty; R A Elton
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  Fluoxymesterone stimulation of tumor marker secretion in patients with breast carcinoma.

Authors:  W G Dilley; D E Haagensen; G S Leight; S Ammirata; S R Davis; J S Silva; N Zamcheck; J J Lokich; S A Wells
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

6.  Growth inhibition of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by controlled-release low-dose medroxyprogesterone acetate.

Authors:  S Li; M Lepage; Y Mérand; A Bélanger; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

7.  Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide.

Authors:  G Boccuzzi; E Tamagno; E Brignardello; M Di Monaco; M Aragno; O Danni
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

8.  Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethyl-benz(a) anthracene in the rat.

Authors:  F Labrie; S Li; A Bélanger; J Côté; Y Mérand; M Lepage
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  Stimulatory effects of androgen and antiandrogen on the in vitro proliferation of human mammary carcinoma cells.

Authors:  R Hackenberg; J Hofmann; F Hölzel; K D Schulz
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

10.  Inhibitory effect of hydroxyflutamide plus tamoxifen on oestradiol-induced growth of MCF-7 breast cancer cells.

Authors:  M Di Monaco; E Brignardello; L Leonardi; V Gatto; G Boccuzzi
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.